Seaport Therapeutics Reports Strong Q1, Extends Cash Runway to 2029, Advances Clinical Pipeline
SPTX is trading near its 52-week low of $14.85 (11% above the low).
Summary
Seaport Therapeutics reported strong first-quarter 2026 financial results, highlighting $212.6 million in cash and equivalents. Combined with $260 million from its recent upsized IPO, this is expected to fund operations into 2029, providing significant financial stability for the clinical-stage company. The company also announced positive new Phase 1 data for GlyphAgo(TM), demonstrating therapeutic exposures while avoiding liver enzyme elevations, which addresses a key safety profile aspect. Enrollment for the Phase 2b BUOY-1 trial of GlyphAllo(TM) is on track, with topline data expected in the first half of 2027. Additionally, Dr. Sharon Mates, a highly experienced executive from Intra-Cellular Therapies, was appointed to the Board of Directors, further strengthening leadership.
At the time of this announcement, SPTX was trading at $16.44 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $871.8M. The 52-week trading range was $14.85 to $19.30. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.